Advertisement

Current Dermatology Reports

, Volume 7, Issue 3, pp 169–179 | Cite as

Iatrogenic Dermatoses in Hospitalized Patients

  • Christina I. Tejeda
  • Stephanie Gallitano
Hospital- based Dermatology (D Kroshinsky, Section Editor)
  • 29 Downloads
Part of the following topical collections:
  1. Topical Collection on Hospital-based Dermatology

Abstract

Purpose of Review

Hospitalized patients are at risk of skin injury from drugs and procedures. These complications carry a high risk of morbidity, mortality, and internal organ involvement. This review examines updates in the treatment of drug eruptions and diagnosis of newly reported iatrogenic skin injuries that accompany novel procedures.

Recent Findings

Drug eruptions are a common cause of iatrogenic injury and they vary in presentation and severity. Recent research suggests that medications such as cyclosporine and etanercept may improve mortality in patients with epidermal necrosis although a randomized controlled trial is still needed. Innovative non-invasive procedures can have cutaneous complications such as radiation injury and microemboli. In immunocompromised patients, seemingly banal clinical manipulation such as application of medical tape can lead to cutaneous infection.

Summary

Physicians should maintain a high index of suspicion for iatrogenic injury when caring for the hospitalized patient. It is crucial to obtain a thorough medication and procedural history when evaluating these patients.

Keywords

Iatrogenic disease Skin injury Hospitalized Emboli Drug rash SJS/TEN 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    American Hospital Association. In: fast facts on U.S. Hospitals, 2018. https://www.aha.org/statistics/fast-facts-us-hospitals.
  2. 2.
    Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. 1991. Qual Saf Health Care. 2004;13(2):145–51. discussion 51–2CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Cheng CE, Kroshinsky D. Iatrogenic skin injury in hospitalized patients. Clin Dermatol. 2011;29(6):622–32.  https://doi.org/10.1016/j.clindermatol.2011.08.006.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Connolly DM, Silverstein DI. Dermatology consultations in a tertiary care hospital: a retrospective study of 243 cases. Dermatol Online J. 2015; 21(8).Google Scholar
  5. 5.
    Storan ER, McEvoy MT, Wetter DA, El-Azhary RA, Camilleri MJ, Bridges AG, et al. Experience of a year of adult hospital dermatology consultations. Int J Dermatol. 2015;54(10):1150–6.  https://doi.org/10.1111/ijd.12555.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Williams A, Bhatia A, Kanish B, Chaudhary PR, Samuel CJ. Pattern of inpatient dermatology consultations in a tertiary care centre from northern India. J Clin Diagn Res. 2016;10(12):WC07–10.  https://doi.org/10.7860/JCDR/2016/21182.8968.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71(5):941–7.  https://doi.org/10.1016/j.jaad.2014.07.016.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, et al. The role of prior corticosteroid use on the clinical course of Stevens–Johnson syndrome and toxic epidermal necrolysis: a case–control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol. 2012;167(3):555–62.  https://doi.org/10.1111/j.1365-2133.2012.11074.x.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol. 2013;79(3):389–98.  https://doi.org/10.4103/0378-6323.110749.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147–76.  https://doi.org/10.1007/s12016-017-8654-z.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187 e1–16; quiz 203–4.  https://doi.org/10.1016/j.jaad.2013.05.002.CrossRefGoogle Scholar
  12. 12.
    Aihara M, Kano Y, Fujita H, Kambara T, Matsukura S, Katayama I, et al. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens–Johnson syndrome and toxic epidermal necrolysis. J Dermatol. 2015;42(8):768–77.  https://doi.org/10.1111/1346-8138.12925.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chong I, Chao A. Stevens-Johnson syndrome/toxic epidermal necrolysis and treatment with a biologic: a case report. Perm J 2017;21. doi:10.7812/TPP/16-060.Google Scholar
  14. 14.
    Didona D, Paolino G, Garcovich S, Caposiena Caro RD, Didona B. Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab. J Eur Acad Dermatol Venereol. 2016;30(10):e83–e4.  https://doi.org/10.1111/jdv.13330.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Firoz BF, Henning JS, Zarzabal LA, Pollock BH. Toxic epidermal necrolysis: five years of treatment experience from a burn unit. J Am Acad Dermatol. 2012;67(4):630–5.  https://doi.org/10.1016/j.jaad.2011.12.014.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    González-Herrada C, Rodríguez-Martín S, Cachafeiro L, Lerma V, González O, Lorente JA, et al. Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Investig Dermatol. 2017;137(10):2092–100.  https://doi.org/10.1016/j.jid.2017.05.022.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Košt́ál M, Bláha M, Lánská M, Košt́álová M, Bláha V, Štepánová E, et al. Beneficial effect of plasma exchange in the treatment of toxic epidermal necrolysis: a series of four cases. J Clin Apher. 2012;27(4):215–20.  https://doi.org/10.1002/jca.21213.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lee HY, Fook-Chong S, Koh HY, Thirumoorthy T, Pang SM. Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol. 2017;76(1):106–13.  https://doi.org/10.1016/j.jaad.2016.07.048.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71(2):278–83.  https://doi.org/10.1016/j.jaad.2014.04.044.CrossRefGoogle Scholar
  20. 20.
    Saavedra C, Cardenas P, Castellanos H, Contreras K, Castro JR. Cephazolin-induced toxic epidermal necrolysis treated with intravenous immunoglobulin and N-acetylcysteine. Case Reports Immunol. 2012;2012:931528–4.  https://doi.org/10.1155/2012/931528.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol. 2013;79(5):686–92.  https://doi.org/10.4103/0378-6323.116738.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    St. John J, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE, et al. Successful use of cyclosporin A for Stevens–Johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol. 2017;34(5):540–6.  https://doi.org/10.1111/pde.13236.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Sun J, Liu J, Gong QL, Ding GZ, Ma LW, Zhang LC, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People’s Republic of China. Drug Des Devel Ther. 2014;8:2539–47.  https://doi.org/10.2147/DDDT.S71736.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y, Nakamura K, Kambara T, et al. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients—treatment and outcome. Allergol Int. 2016;65(1):74–81.  https://doi.org/10.1016/j.alit.2015.09.001.CrossRefGoogle Scholar
  25. 25.
    Yavuz H, Emiroglu M. Toxic epidermal necrolysis treated with N-acetylcysteine. Pediatr Int. 2014;56(5):e52–4.  https://doi.org/10.1111/ped.12410.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Das S, Roy A, Biswas I. A six-month prospective study to find out the treatment outcome, prognosis and offending drugs in toxic epidermal necrolysis from an urban institution in Kolkata. Indian Journal of Dermatology. 2013;58(3):191–3.  https://doi.org/10.4103/0019-5154.110826.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol. 2012;66(6):995–1003.  https://doi.org/10.1016/j.jaad.2011.09.029.CrossRefGoogle Scholar
  28. 28.
    Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(6):514–22.  https://doi.org/10.1001/jamadermatol.2016.5668.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mattoussi N, Ben Mansour A, Essadam L, Guedri R, Fitouri Z, Ben Becher S. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in children: a case report. J Investig Allergol Clin Immunol. 2017;27(2):144–6.  https://doi.org/10.18176/jiaci.0140.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Vinson AE, Dufort EM, Willis MD, Eberson CP, Harwell JI. Drug rash, eosinophilia, and systemic symptoms syndrome: two pediatric cases demonstrating the range of severity in presentation—a case of vancomycin-induced drug hypersensitivity mimicking toxic shock syndrome and a milder case induced by minocycline. Pediatr Crit Care Med. 2010;11(4):e38–43.  https://doi.org/10.1097/PCC.0b013e3181c5911a.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Matta JM, Flores SM, Cherit JD. Drug reaction with eosinophilia and systemic symptoms (DRESS) and its relation with autoimmunity in a reference center in Mexico. An Bras Dermatol. 2017;92(1):30–3.  https://doi.org/10.1590/abd1806-4841.20175190.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management. Expert Opin Drug Saf. 2017;16(2):139–47.  https://doi.org/10.1080/14740338.2017.1270940.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Funck-Brentano E, Duong TA, Bouvresse S, Bagot M, Wolkenstein P, Roujeau JC, et al. Therapeutic management of DRESS: a retrospective study of 38 cases. J Am Acad Dermatol. 2015;72(2):246–52.  https://doi.org/10.1016/j.jaad.2014.10.032.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Kirchhof MG, Wong A, Dutz JP. Cyclosporine treatment of drug-induced hypersensitivity syndrome. JAMA Dermatol. 2016;152(11):1254–7.  https://doi.org/10.1001/jamadermatol.2016.2220.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Zhang ZX, Yang BQ, Yang Q, Wu M, Wang GJ. Treatment of drug-induced hypersensitivity syndrome with cyclosporine. Indian J Dermatol Venereol Leprol. 2017;83(6):713–7.  https://doi.org/10.4103/ijdvl.IJDVL_1084_16.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Stern RS. Clinical practice. Exanthematous drug eruptions. N Engl J Med. 2012;366(26):2492–501.  https://doi.org/10.1056/NEJMcp1104080.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73(5):843–8.  https://doi.org/10.1016/j.jaad.2015.07.017.CrossRefGoogle Scholar
  38. 38.
    Kostopoulos TC, Krishna SM, Brinster NK, Ortega-Loayza AG. Acute generalized exanthematous pustulosis: atypical presentations and outcomes. J Eur Acad Dermatol Venereol. 2015;29(2):209–14.  https://doi.org/10.1111/jdv.12721.CrossRefPubMedGoogle Scholar
  39. 39.
    Plum M, Moukhachen O. Alternative pharmacological management of vasopressor extravasation in the absence of phentolamine. P T. 2017;42(9):581–92.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Park HJ, Kim KH, Lee HJ, Jeong EC, Kim KW, Suh DI. Compartment syndrome due to extravasation of peripheral parenteral nutrition: extravasation injury of parenteral nutrition. Korean J Pediatr. 2015;58(11):454–8.  https://doi.org/10.3345/kjp.2015.58.11.454.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Al-Benna S, O'Boyle C, Holley J. Extravasation injuries in adults. ISRN Dermatol. 2013;2013:856541.  https://doi.org/10.1155/2013/856541.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6):617–32.  https://doi.org/10.1002/phar.1396.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Camargo D, Saad C, Ruiz F, Ramirez ME, Lineros M, Rodriguez G, et al. Iatrogenic outbreak of M. chelonae skin abscesses. Epidemiol Infect. 1996;117(1):113–9.CrossRefPubMedCentralGoogle Scholar
  44. 44.
    Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, et al. Healthcare-associated mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S44–54.  https://doi.org/10.1093/cid/cir867.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Mead JH, Lupton GP, Dillavou CL, Odom RB. Cutaneous rhizopus infection: occurrence as a postoperative complication associated with an elasticized adhesive dressing. JAMA. 1979;242(3):272–4.  https://doi.org/10.1001/jama.1979.03300030044022.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Everett E, Pearson S, Rogers W. Rhizopus surgical wound infection associated with elasticized adhesive tape dressings. Arch Surg. 1979;114(6):738–9.  https://doi.org/10.1001/archsurg.1979.01370300092019.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Lalayanni C, Baliakas P, Xochelli A, Apostolou C, Arabatzis M, Velegraki A, et al. Outbreak of cutaneous zygomycosis associated with the use of adhesive tape in haematology patients. J Hosp Infect. 2012;81(3):213–5.  https://doi.org/10.1016/j.jhin.2012.04.007.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    McClusky J, Davis M, Dahl K. A gap in patient tape storage and use practices puts patients at risk for cutaneous fungal infections. Am J Infect Control. 2015;43(2):182–4.  https://doi.org/10.1016/j.ajic.2014.10.028.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Lachapelle JM. A comparison of the irritant and allergenic properties of antiseptics. Eur J Dermatol. 2014;24(1):3–9.  https://doi.org/10.1684/ejd.2013.2198.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Opstrup MS, Johansen JD, Zachariae C, Garvey LH. Contact allergy to chlorhexidine in a tertiary dermatology clinic in Denmark. Contact Dermatitis. 2016;74(1):29–36.  https://doi.org/10.1111/cod.12487.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Cordoba S, Sanz-Sanchez T, Mohedano-Vicente E, Borbujo J. Allergic contact dermatitis due to chlorhexidine in 2 pediatric patients. Actas Dermosifiliogr. 2018;  https://doi.org/10.1016/j.ad.2017.10.018.
  52. 52.
    Ozkaya E, Kavlak BP. Allergic contact dermatitis caused by self-adhesive electrocardiography electrodes: a rare case with concomitant roles of nickel and acrylates. Contact Dermatitis. 2014;70(2):121–3.  https://doi.org/10.1111/cod.12146.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Widman TJ, Oostman H, Storrs FJ. Allergic contact dermatitis from medical adhesive bandages in patients who report having a reaction to medical bandages. Dermatitis. 2008;19(1):32–7.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Lyons AB, Harvey VM, Gusev J. Fluoroscopy-induced chronic radiation dermatitis (FICRD) after endovascular abdominal aortic aneurysm endoleak repair. JAAD Case Rep. 2015;1(6):403–5.  https://doi.org/10.1016/j.jdcr.2015.09.022.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Spiker A, Zinn Z, Carter WH, Powers R, Kovach R. Fluoroscopy-induced chronic radiation dermatitis. Am J Cardiol. 2012;110(12):1861–3.  https://doi.org/10.1016/j.amjcard.2012.08.023.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Lee BL, Ma H, Perng CK, Wang TH, Liao WC, Yeh FL, et al. Clinical manifestation, diagnosis, and surgical treatment of chronic radiation ulcers related to percutaneous coronary intervention. Ann Plast Surg. 2016;76(Suppl 1):S68–73.  https://doi.org/10.1097/SAP.0000000000000688.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–322.  https://doi.org/10.1161/CIR.0000000000000152.CrossRefGoogle Scholar
  58. 58.
    Khouzam RN, Soufi MK, Nakhla R, Naidu SS. Outpatient percutaneous coronary intervention: has its time come? J Invasive Cardiol. 2014;26(12):E167–9.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Kirkwood ML, Arbique GM, Guild JB, Timaran C, Valentine RJ, Anderson JA. Radiation-induced skin injury after complex endovascular procedures. J Vasc Surg. 2014;60(3):742–8.  https://doi.org/10.1016/j.jvs.2014.03.236.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Boncher J, Bergfeld WF. Fluoroscopy-induced chronic radiation dermatitis: a report of two additional cases and a brief review of the literature. J Cutan Pathol. 2012;39(1):63–7.  https://doi.org/10.1111/j.1600-0560.2011.01754.x.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Wei KC, Yang KC, Mar GY, Chen LW, Wu CS, Lai CC, et al. STROBE—radiation ulcer: an overlooked complication of fluoroscopic intervention: a cross-sectional study. Medicine (Baltimore). 2015;94(48):e2178.  https://doi.org/10.1097/MD.0000000000002178.CrossRefGoogle Scholar
  62. 62.
    Reichman EF. Fluoroscopy-induced radiation dermatitis. J Emerg Med. 2014;47(5):e117–9.  https://doi.org/10.1016/j.jemermed.2014.06.054.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Meghrajani CF, Co HC, Ang-Tiu CM, Roa FC. Topical corticosteroid therapy for the prevention of acute radiation dermatitis: a systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2013;6(6):641–9.  https://doi.org/10.1586/17512433.2013.841079.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Nishimoto S, Fukuda K, Kawai K, Fujiwara T, Tsumano T, Fujita K, et al. Supplementation of bone marrow aspirate-derived platelet-rich plasma for treating radiation-induced ulcer after cardiac fluoroscopic procedures: a preliminary report. Indian J Plast Surg. 2012;45(1):109–14.  https://doi.org/10.4103/0970-0358.96599.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Mohan A, Singh S. Use of fat transfer to treat a chronic, non-healing, post-radiation ulcer: a case study. J Wound Care. 2017;26(5):272–3.  https://doi.org/10.12968/jowc.2017.26.5.272.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Oka H, Kamimura T, Hiramatsu Y, Fukumitsu K, Iwata R, Kondo M, et al. Cholesterol crystal embolism induced by direct factor Xa inhibitor: a first case report. Intern Med. 2018;57(1):71–4.  https://doi.org/10.2169/internalmedicine.8660-16.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Donohue KG, Saap L, Falanga V. Cholesterol crystal embolization: an atherosclerotic disease with frequent and varied cutaneous manifestations. J Eur Acad Dermatol Venereol. 2003;17(5):504–11.CrossRefGoogle Scholar
  68. 68.
    Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol. 1988;62(16):1109–12.CrossRefPubMedCentralGoogle Scholar
  69. 69.
    Saric M, Kronzon I. Cholesterol embolization syndrome. Curr Opin Cardiol. 2011;26(6):472–9.  https://doi.org/10.1097/HCO.0b013e32834b7fdd.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Pathmarajah T, Abdelhamid M, Tenna AS, Paton DJW, Hockley JA, Jansen S. Acute global testicular infarction post-EVAR from cholesterol embolisation can be mistaken for torsion. EJVES Short Rep. 2017;35:11–5.  https://doi.org/10.1016/j.ejvssr.2017.03.002.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Maekawa M, Sugino N, Watanabe K, Nomura R. Multiple brain infarction associated with cholesterol embolization syndrome. Intern Med. 2017;56(18):2531–3.  https://doi.org/10.2169/internalmedicine.8733-16.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Li X, Bayliss G, Zhuang S. Cholesterol crystal embolism and chronic kidney disease. Int J Mol Sci. 2017;18(6):1120.  https://doi.org/10.3390/ijms18061120.CrossRefGoogle Scholar
  73. 73.
    Azuma S, Ikenouchi M, Akamatsu T, Seta T, Urai S, Uenoyama Y, et al. Ileus caused by cholesterol crystal embolization: a case report. World J Gastroenterol. 2016;22(12):3502–5.  https://doi.org/10.3748/wjg.v22.i12.3502.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Thompson AK, Peters MS, El-Azhary RA, Gibson LE, Chang MB, Griffin JR, et al. Cutaneous microemboli from hydrophilic polymer after endovascular procedures. J Am Acad Dermatol. 2015;73(4):666–71.  https://doi.org/10.1016/j.jaad.2015.07.014.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Hamidi S, Stevens R, DeClerck B, Kim GH. Hydrophilic polymer microemboli in a patient with a chronic cutaneous ulcer: a case report. J Cutan Pathol. 2014;41(12):955–8.  https://doi.org/10.1111/cup.12420.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Sequeira A, Parimoo N, Wilson J, Traylor J, Bonsib S, Abreo K. Polymer embolization from minimally invasive interventions. Am J Kidney Dis. 2013;61(6):984–7.  https://doi.org/10.1053/j.ajkd.2012.12.021.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    El-Najjar V, Robinson M. Autopsy demonstration of intramyocardial polymer gel emboli associated with a giant-cell reaction following cardiac catheterization: a case report. Cardiovasc Pathol. 2012;21(1):59–61.  https://doi.org/10.1016/j.carpath.2011.05.005.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Danowski KM, Morrison M, Ghaferi J, Cotton J. Hydrophilic polymer embolization: an emerging cause of livedo reticularis. J Cutan Pathol. 2014;41(11):813–5.  https://doi.org/10.1111/cup.12434.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Goto K, Takai T, Nishimura K, Oshitani Y. Hydrophilic polymer microembolism with cutaneous involvement observed incidentally in a patient undergoing endovascular procedures: a case report. J Cutan Pathol. 2016;43(7):632–4.  https://doi.org/10.1111/cup.12711.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Hardy CL, Glass JS, Sorrells T, Nicholas LC. Hemorrhagic panniculitis caused by delayed microemboli from intravascular device. JAMA Dermatol. 2015;151(2):204–7.  https://doi.org/10.1001/jamadermatol.2014.2393.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Han F, Zhang J, Guo Q, Feng Y, Gao Y, Guo L, et al. Successful treatment of toxic epidermal necrolysis using plasmapheresis: a prospective observational study. J Crit Care. 2017;42:65–8.  https://doi.org/10.1016/j.jcrc.2017.07.002.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Columbia Vagelos College of Physicians and SurgeonsNew YorkUSA
  2. 2.Department of DermatologyColumbia University Medical CenterNew YorkUSA

Personalised recommendations